

# Collaboration between the IC & the MSCI



**MARIA SKŁODOWSKA CURIE'S DREAM HAS COME TRUE**

**institut Curie**

**Maria Skłodowska-Curie National Research Institute of Oncology**

**Prof. Steven Le Gouill,**  
Chairman of the Executive Board

**Prof. Alain Puisieux,**  
Director of the Research Center

**Prof. Thierry Philip,**  
Former Director

**Prof. Besta Jagielska**  
Director

**Prof. Michal Mikula**  
Scientific Director

**Prof. Iwona Ługowska,**  
Director of International Affairs  
Head of Center for Excellence  
in Precision Medicine

The image features a map of Europe with Paris and Warsaw highlighted. Surrounding the map are portraits of six individuals, each with a caption identifying their role in the collaboration. The background includes the logos of Institut Curie and the Maria Skłodowska-Curie National Research Institute of Oncology.

Organisation of European Cancer Institutes - EEIG





*"My family is of Polish origin,  
and my name is Marie Skłodowska."*

– MARIA SKŁODOWSKA-CURIE

President Harding welcomed Maria on behalf of the  
American people, calling her the *"adopted daughter  
of France"* and the *"native-born daughter of Poland"*

## FAMILY



BRONISŁAWA  
BOGUSKA  
MOTHER



WŁADYSŁAW  
SKŁODOWSKI  
FATHER



SIBLINGS



PRESIDENT WARREN  
G. HARDING AND MARIA  
THE GRAM OF RADIUM FOR FRANCE



MARIE ("MISSY") MELONEY WITH  
IRÈNE, MARIE, AND EVE CURIE  
IN NEW YORK CITY ON MAY 12, 1921



PRESIDENT HERBERT HOOVER  
AND MARIA  
THE GRAM OF RADIUM FOR POLAND






# Collaboration between the IC & the MSCI



Marie Curie's trip to the United States: looking back on 100 years of history .



*In Washington, 2021, the two organizations mutually agreed to enter into the MoU with the understanding that the relationship thus established would form the foundation for developing joint activities leading to further growth in the esteem of both organizations.*



Organisation of European Cancer Institutes - EEIG



# Collaboration between the IC & the MSCJ




C4C  
Curie  
for  
Curie



Organisation of European Cancer Institutes - EEIG








**Plans of C4C are to promote a high-quality cancer research on prevention, diagnosis, treatment and its outcomes in the following ways:**

- a. Innovative Advances in Cancer Research**
- b. New technologies**
- c. Data Management and Data Sharing**
- d. Education and training**



# Collaboration between the IC & the MSCl



MARCH 2023						
Su	Mo	Tu	We	Th	Fr	Sa
			1★	2	3	4
5	6★	7	8★	9★	10★	11
12	13★	14	15★	16	17	18
19	20	21	22★	23	24★	25
26	27★	28	29★	30★	31	

APRIL 2023						
Su	Mo	Tu	We	Th	Fr	Sa
						1
2	3★	4	5	6	7	8
9	10	11	12	13★	14	15
16	17	18	19★	20	21	22
23	24★	25	26	27	28	29
30						

MAY 2023						
Su	Mo	Tu	We	Th	Fr	Sa
	1	2	3	4	5	6
7	8	9	10	11	12★	13
14	15	16	17★	18	19	20
21	22	23	24	25	26	27
28	29	30★	31			

JUNE 2023						
Su	Mo	Tu	We	Th	Fr	Sa
				1	2	3
4	5★	6	7	8	9★	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	


★ Kick-off meeting

★ Follow-up meeting

Organisation of European Cancer Institutes - EEIG




# Collaboration between the IC & the MSCl



Project	Maria Sklodowska Curie National Cancer Institute	Institut Curie
Lung cancer	Prof. Maciej Krzakowski Dr Magdalena Knetki-Wroblewska	Prof. Nicolas Girard Dr Helen Salmon Dr Clemence Basse
Preclinical research EurOPDX	Prof. Michal Mikula	Dr Sergio Roman Roman
Cancer of unknown primary	Dr Aleksandra Kapala Dr Konrad Talasiewicz Dr Andrzej Tysarowski	Prof. Christophe Le Tourneau Dr Maud Kamal
Precision oncology	Prof. Iwona Lugowska Marcin Witczak Andrzej Tysarowski	Prof. Christophe Le Tourneau

Organisation of European Cancer Institutes - EEIG





*MARIA SKŁODOWSKA CURIE'S DREAM HAS COME TRUE...*

PROJECT TITLE: Early phase clinical trials as viable therapeutic option for cancer patients

Collaboration between  
EARLY PHASE CLINICAL TRIALS UNIT, MSCI, WARSAW, POLAND  
AND DRUG DEVELOPEMENT AND INNOVATION DEPARTMENT, IC, PARIS



Prof. Iwona Lugowska



Prof. Christophe Le Tourneau





- **Data Sharing and Analyzing:**

- Sharing EP (and molecular) clinical trial data in federated mode.
- Analyzed the impact of innovative therapy.

- **Global Impact:**

- Increase visibility of Curie's activities in the scientific and medical community.
- Leverage expertise based on the EU projects focused on precision oncology
- Molecular Tumor Boards.
- Promote reducing inequalities in research.

- **Attracting New Talent - Involvement of Young Scientists:**

- Attract and involve young scientists in EP trial research.



- Phase I trials primarily aim to evaluate the safety of new therapies.
- Many cancer patients, especially those who have exhausted standard treatment options, enroll in these trials hoping for clinical benefits specially with recent advances in drug development, including targeted therapies and immunotherapies.
- There remains a gap in understanding the clinical benefits of these trials in terms of overall survival and trial safety.

## Aim

- Assess the clinical benefit and the impact on overall survival
- Compare outcomes of patients who were:
  - Successfully enrolled in EP trials
  - Fail (pre)screening and thus explore its reasons



All subsequent patients consulted in EP Departments between January 2018, and December 2023  
✓ to date, data from 1226 French patients, and 1200 Polish patients have been gathered



# Collaboration between the IC & the MSCl



Datum: Di. 10. Juni 2025 um 20:55

Betreff: MAP Congress 2025: Abstract submission confirmation

An: Pawel Michalak <[pawelmichalak09@gmail.com](mailto:pawelmichalak09@gmail.com)>


Dear Dr. Michalak,

Thank you for having submitted your abstract to the MAP Congress 2025.


Your abstract **#414 - Clinical outcomes of patients enrolled into early-phase oncology trials: a single-center retrospective analysis** will be reviewed by the Scientific Committee and the outcome notification will be sent to the first author in mid-August 2025.



# Collaboration between the IC & the MSCI



September 2022  
Prof. Ługowska – Editor; Prof. Le Tourneau – author of  
Chapter 8. Molecular Markers in Clinical Practice



Clinical Trial > Lancet Oncol. 2023 Aug;24(8):925-935.

doi: 10.1016/S1470-2045(23)00275-9.

## Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant<sup>1</sup>, Martin Schuler<sup>2</sup>, Gopa Iyer<sup>3</sup>, Olaf Witt<sup>4</sup>, Toshihiko Doi<sup>5</sup>, Shukui Qin<sup>6</sup>, Josep Tabernero<sup>7</sup>, David A Reardon<sup>8</sup>, Christophe Massard<sup>9</sup>, Anna Minchom<sup>10</sup>, Iwona Ługowska<sup>11</sup>, Omar Carranza<sup>12</sup>, Dirk Arnold<sup>13</sup>, Martin Gutierrez<sup>14</sup>, Helen Winter<sup>15</sup>, Kim Stuyckens<sup>16</sup>, Lauren Crow<sup>17</sup>, Saltanat Najmi<sup>17</sup>, Constance Hammond<sup>17</sup>, Shibu Thomas<sup>17</sup>, Ademi Santiago-Walker<sup>17</sup>, Spyros Triantos<sup>17</sup>, Hussein Sweiti<sup>17</sup>, Yohann Loriot<sup>18</sup>; RAGNAR Investigators

Collaborators, Affiliations — collapse

### Collaborators

**RAGNAR Investigators:** Omar Carranza, Martin Alberto Greco, Jim Coward, Anthony Joshua, Christos Karapetis, Christopher Hart, Alison Zhang, Hans Prenen, Jean-Charles Goeminne, Jean-Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Tiscoski, Denis Leonardo Fontes Jardim, Milena Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Shukui Qin, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean-Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schuler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Cazzaniga, Fortunato Ciardiello, Michele Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jungyun Lee, Sung-Bae Kim, Myung-Ju Ahn, Jong Hee Chang, Yong-Man Kim, Do-Hyun Nam, Jae-Sung Park, Iwona Ługowska, Luis Paz-Ares, Victor Moreno, Andres Cervantes, Mariona Calvo, Alejandro Falcon, Antonio Gonzalez, Josep Tabernero, Alejandro Martinez Bueno, Javier Garcia-Corbacho, Federico Longo, Chia-Jui Yen, Jen-Shi Chen, Ming-Feng Hou, Yee Chao, Kun-Ming Rau, Tai-Jan Chiu, Yin-Hsun Feng, Chih-Hung Hsu, Wen-Tsung Huang, Kuan-Ming Lai, Su-Peng Yeh, Daniel Palmer, Anna Minchom, Helen Winter, Liam Welsh, Ruth Plummer, Gopakumar Iyer, Martin Gutierrez, Mehmet Bilen, Edward Arrowsmith, Shubham Pant, David Robert Spigel, Dan Paul Zandberg, Deborah Doroshow, Christine Lu-Emerson, Mehdi Moezi, Scott Paulson, David Reardon, Patrick Ward, Jorge Chaves, Claud Grigg, Atif Hussein, Sudhir Manda, Michael Monticelli, Rubina Qamar, Stephen L Richey, David Tamura, Sharon Wilks

August 2023 – Lancet Oncology

Organisation of European Cancer Institutes - EEIG







# Collaboration between the IC & the MSCl



**CAN.HEAL - BUILDING THE EU CANCER AND PUBLIC HEALTH GENOMICS PLATFORM**


Project duration: 01/11/2022-30/04/2025

43 INSTITUTIONS FROM 17 EU COUNTRIES


**Curie joint participation on WORK PACKAGE 8 (Leader Prof.Le Tourneau, IC)**

**– guidelines on MTB organization**


can.heal



Organisation of European Cancer Institutes - EEIG



## JA PCM GENERAL STRUCTURE





# Collaboration between the IC & the MSCl



## JANE – SHAPING THE EU NETWORKS OF EXPERTISE ON CANCER (project duration: 2024-2028)

### Curie joint effort on WORK PACKAGE 5 – complex and poor prognosis cancer


Work Package 5: complex and poor prognosis cancer (PPC)			
Duration:	M1 – M48	Lead Beneficiary:	Maria Skłodowska Curie National Research Institute of Oncology - MSCl
Objectives			
<p>Given the rising incidence trends and low survival rates, poor prognosis cancers (PPC), such as pancreatic and lung cancer, are emerging health challenges. Although these two cancers constitute 3% and 12% of new cancer diagnoses within the EU, they account for 29% and 20% of cancer-related deaths, respectively. Developing a roadmap for establishing and expanding NoE for cancers with a 5-year overall survival below 33% is crucial. This initiative aims to address the needs of patients with poor prognosis cancers and implement an action plan to enhance survival rates while maintaining a good quality of life. The specific objectives are as follows:</p> <ol style="list-style-type: none"><li>1. to organise NoE for <b>pancreatic cancer</b> and NoE for <b>lung cancers</b>, and, based on these experiences, develop a <b>roadmap for further NoEs</b> addressing public health priorities for PPC patients (T5.1),</li><li>2. to support the development of <b>clinical guidelines/pathways</b> from early diagnosis to palliative care in the treatment process to promote high-quality cancer care and tackle cancer inequalities in Europe (T5.2),</li><li>3. to promote novel <b>translational research</b> programmes to foster high-tech solutions and innovation in PPC (T5.3),</li><li>4. to <b>educate</b> the community about PPC, proactively <b>involve</b> patient advocacy groups and stakeholders, and assist them in the wide dissemination of relevant information about PPC using educational tools or collaborative networks (T5.4),</li><li>5. to collaborate with <b>policymakers</b> to promote optimised care and increase/facilitate access to innovation for individuals with PPC; to support the implementation of early access to diagnostics, care, and supportive/palliative care (T5.5),</li><li>6. to ensure effective <b>NoE PPC governance, dissemination, evaluation, and sustainability</b> (T5.6).</li></ol>			



Task 3 - Research and Innovation – Leader Prof. Le Tourneau

Task 6 – Governance – Leader Prof. Iwona Ługowska

Organisation of European Cancer Institutes - EEIG





## POLISH-FRENCH PHD BETWEEN TWO EP DEPARTMENTS; FRENCH GOVERNMENT SCHOLARSHIP

Dear Ms Agnieszczak,

Following your application to the French Government scholarship for a scientific stay during your PhD, **we have the great pleasure to confirm that you have been selected as a laureate** for the 2025 Program. Congratulations! We would like to thank you for your interest and congratulate you on the quality of your research project.

Chère Madame Agnieszczak,

Suite à votre candidature au programme de bourse du gouvernement français dans le cadre de votre doctorat, le **pôle de coopération scientifique et universitaire de l'ambassade de France en Pologne** a l'immense plaisir de vous confirmer que vous avez été sélectionné(e) comme lauréat(e) pour le Programme 2025. Nous vous adressons toutes nos félicitations et tenons à vous remercier pour votre intérêt et à vous féliciter pour la qualité de votre projet de recherche.

**Aurore PETIT**  
Chargée de coopération scientifique et universitaire  
Service de coopération et d'action culturelle (SCAC)  
Ambassade de France en Pologne



JULY-AUGUST 2023

AUGUST 2024

MAY 2025


Organisation of European Cancer Institutes - EEIG





## COMMON INTEREST IN PRECISION ONCOLOGY

**POLARIS – A PHASE 2 OPEN-LABEL PRECISION ONCOLOGY  
TUMOROID-ENHANCED MULTI-DTUG REPURPOSING STUDY  
IN NON-OPERABLE/METASTATIC CANCER**



☐ NCT06459791 **Recruiting**

Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid

### Conditions

Metastatic Breast Cancer

### Locations

Paris, France (2)

Saint-Cloud, France


  
institut  
Curie

MEDICAL RESEARCH AGENCY – RESULTS IN JUNE 2025

Organisation of European Cancer Institutes - EEIG



*MARIA SKŁODOWSKA CURIE'S DREAM HAS COME TRUE...*



Collaboration between

LUNG CANCER DEPT , MSCI, WARSAW, POLAND

AND

LUNG CANCER DEPARTMENT, IC, PARIS

PROJECT TITLE: **STEREO-LUNG**

TREATMENT OF OLIGOPROGRESSIVE DISEASE

FOR PATIENTS UNDER IMMUNOTHERAPY IN 1ST LINE OF METASTATIC NSCLC





## STEREO-LUNG STUDY

### MATERIALS & METHODS

- retrospective & observational multicentre study (Curie Institute – Paris & Warsaw)
- 61 stage IV NSCLC patients
- adenocarcinoma vs squamous-cell carcinoma & other histology – 69% vs 31%
- PD-L1  $\geq$  50% vs  $<$  50% – 63% vs 37%
- first-line immunotherapy (single-agent – 39%, combined with chemotherapy – 61%)
- oligoprogressive disease according to the EORTC definition
- local ablative treatment – resection / radiotherapy, radiofrequency ablation

*\* Huet et al. Clin Lung Cancer 2024;; 18: 52-60*



Multicenter Study

➤ Clin Lung Cancer. 2024 Dec;25(8):e402-e410.e3.

doi: 10.1016/j.clcc.2024.07.009. Epub 2024 Aug 8.

## Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy

C Huet<sup>1</sup>, C Basse<sup>2</sup>, M Knetki-Wroblewska<sup>3</sup>, P Chilczuk<sup>3</sup>, P E Bonte<sup>4</sup>, S Cyrille<sup>5</sup>, E Gobbini<sup>6</sup>,  
P Du Rusquec<sup>6</sup>, M Olszyna-Serementa<sup>3</sup>, C Daniel<sup>6</sup>, F Lucibello<sup>6</sup>, L Lahmi<sup>7</sup>, M Krzakowski<sup>3</sup>,  
N Girard<sup>8</sup>

Clin Lung Cancer. 2024; 25(8):e402-e410




# CURIE4CURIE COOPERATION

## THORACIC MALIGNANCIES


### FURTHER STEPS IN MULTICENTRE ANALYSES

- postoperative radiotherapy in patients with thymomas
- management of locally advanced NSCLC patients with failure of durvalumab consolidation therapy following concurrent radiochemotherapy





## *MARIA SKŁODOWSKA CURIE'S DREAM HAS COME TRUE...*



### Collaboration between

Aleksandra Kapała, Department of Oncology Diagnostics, MSCl,  
WARSAW, POLAND

AND

Sarah Watson, National CUP MTB ,IC, PARIS, FRANCE

Clinical, molecular and anatomopathological characterization  
of patients with Carcinoma of Unknown Primary (CUP)  
using the experience of the French National CUP Molecular  
Tumor Board



## ✓ MSCI Team training : visit of Institut Curie Paris – Sept 2024







Coordination:  
*Institut Curie*


Medical coordinators :  
*Pr Christophe Le Tourneau & Dr Sarah Watson*  
*Pr. Janick Selves*  
*Dr. Etienne Rouleau*

National experts committee :  
*Oncologists, pathologists and molecular biologists*

- Twice a month
- **Eligibility** : all patient with metastatic cancer, at all stages, for which the tumor of origin remains unidentified
- **Objectives** :
  - Centralization of additional analyzes & interpretation of results
  - Therapeutic recommandation
  - Clinico-biological database


<https://pfmg2025.aviesan.fr/professionnels/preindications-et-mise-en-place/cancers-de-primitif-inconnu/>





# C4C PROJECT





The aim is **to develop a translational research program capitalizing on available experience in IC** to:

- 1) organize a **MTB for CUP patients at MSCI**
- 2) develop the **Curie protocol/SOP for fresh frozen tissue processing and biobanking at MSCI** for adequate expression profiling and DNA methylation profiling for future research projects
- 3) build the **repository of CUP tissues** in Curie Institutes

The **Biobank** is an organizational unit of the MSCI, established on June 1, 2023 (Order No. 32/2023 of the MSCI Director).


Its primary objective is **biobanking**, which involves the **process** of acquiring and storing, along with some or all activities related to the collection, preparation, preservation, examination, analysis, and distribution of specific biological material, as well as the associated information and data.

The collected biological material is intended primarily for conducting **scientific research** and **development work** in the field of cancer diseases and for adapting and implementing the results of this work into clinical practice, developing new therapies and medications, and creating innovative diagnostic technologies

**The possibility of carrying out a research project using biological material must be preceded by obtaining a positive opinion from the Bioethics Committee and informed consent from the Patient/Donor for the biobanking of such biological material.**

The Biobank collects various types of biological materials such as **blood and its isolated components** and **tissue samples**.

**Routine methods:** *snap-frozen, cryopreservation* both  $-86^{\circ}\text{C}$  and  $-150^{\circ}\text{C}$  (LN2 cryotank) are available.



*The development of the Biobank is possible due to funds obtained under the project “Regional Center for Digital Medicine in Oncology: Innovative Data Analysis Solutions and Technologies for an Intelligent Cancer Research Ecosystem” (2023–2028); it includes **MSCI infrastructural modernization, equipment and IT system supplementation**.*






- ✓ Transfer of documentations for IC Paris to MSCI team (SOPs, charters for MTBs, sequencing protocols, workflow of the National French Genomic Medicine Initiative 2025)
- ✓ Implementing into the daily practice Polish CUP-MTB workflow
- ✓ Methylation analyses : EPIC analyses ongoing for 5 CUP patients at IC Paris (transport of biological material to IC Paris)
- ✓ Retrospective analysis of CUP patients tissues, searching for CUP-like tumours (next project)

Next steps :

- MSCI team to assist to a French NAT CUP MTB

*MARIA SKŁODOWSKA CURIE'S DREAM HAS COME TRUE...*



## Collaboration between

Department of Genetics, MSCI, WARSAW, POLAND AND  
Translational Research Department, IC, PARIS, FRANCE

The MTARC enzymes as a potential breast cancer subtype biomarker,  
towards the clarification of MTARC1/2 protein role in breast cancer  
tumorigenesis and metabolism

**CURIE DAY**  
Warsaw, 10th January 2025

Organisation of European Cancer Institutes - EEIG



# PROJECT COORDINATORS



MICHAL MIKULA



ELISABETTA MARANGONI





# NATIONAL RESEARCH INSTITUTE OF ONCOLOGY, Warsaw

---



National Research Institute of Oncology  
Warsaw



Cancer Prevention Center

# NATIONAL RESEARCH INSTITUTE OF ONCOLOGY

---



National Research Institute of Oncology  
Cracow



National Research Institute of Oncology  
Gliwice





(Warsaw, data for 2024)

**111,000**

hospitalizations (including 85,000 one-day hospitalizations)

**470,000**

outpatient visits

**134,000**

pathological examinations

**14,000**

genetic tests

**10,000**

surgical procedures

**11,000**

radiotherapy procedures

**107,000**

chemotherapy sessions / drug program treatments





# CURIE DAY

## Warsaw, 10th January 2025

18-20 June 2025, Paris



Paris  
Centre Scientifique  
Académie Polonaise des Sciences



*5<sup>th</sup> International Conference on Quality in Medicine, Global Health and Law  
The Role of International Collaboration in Facilitating Cancer Research  
in Poland and in France*

### AGENDA

#### Wednesday, June 18, 2025

15:00-17:00 Meeting at the Embassy of the Republic of Poland in France, 57 Rue Saint Dominique, 75007 Paris

#### Thursday, June 19, 2025

Polish Academy of Sciences, 74 rue Lauriston, 75116 Paris

09:00-09:30 Registration

09:30-09:50 Opening Remarks - Dr Małgorzata Nabiałczyk-Chalupowski & Prof. Christine Huttin & Prof. Beata Jagielska

#### SESSION - CURIE 4 CURIE (C4C) PROGRAM

09:50-09:55 Introduction - Prof. Iwona Ługowska

09:55-10:35 Overview and preliminary results of research projects (10-minute presentation)

- STEREO-LUNG – Analysis of prolonged progression free survival after ablative treatment of oligo-progressive disease for patients under immunotherapy in 1st line of a metastatic NSCLC, pooled retrospective cohorts from Institute Curie (Paris) & Maria Skłodowska-Curie Institute
- Clinical, molecular and anatomopathological characterization of patients with Carcinoma of Unknown Primary (CUP) using the experience of the French National CUP Molecular Tumor Board (Curie CUP Cooperation, 3C project
- Early phase clinical trials as viable therapeutic option for cancer patients
- The MTARC enzymes as a potential breast cancer subtypes biomarkers, towards the clarification of MTARC1/2 protein role in breast cancer tumorigenesis and metabolism

09:35-10:50 Q&A and future directions – Dörthe Nickel



10:50-11:00 Summary – Prof. Thierry Philip & Prof. Michał Mikula & Prof. Tomasz Rutkowski

11:00-11:10 Coffee break

# Organisation of European Cancer Institutes - EEIG



*MARIA SKŁODOWSKA CURIE'S DREAM HAS COME TRUE...*





## Member Profiles

Homepage > The OEI Network > Member Profiles


**COUNTRY**

- Algeria
- Austria
- Belgium
- Brazil
- Bulgaria
- Chile
- Colombia
- Croatia
- Cyprus

 **POLAND**


---

- Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy**  
 Maria Skłodowska-Curie National Research Institute of Oncology  
<https://www.pib-nio.pl/>  
 ID: 129 **Full Member**





*MARIA SKŁODOWSKA CURIE'S DREAM HAS COME TRUE...*



**Sent:** Monday, June 9, 2025 9:27 AM  
**To:** Iwona Ługowska  
**Subject:** FW: Application OEI A&D Programme

**From:** Willien Westerhuis <[W.Westerhuis@iknl.nl](mailto:W.Westerhuis@iknl.nl)>  
**Sent:** Monday, June 9, 2025 8:57 AM  
**To:** Michał Mikula <[Michal.Mikula@nio.gov.pl](mailto:Michal.Mikula@nio.gov.pl)>  
**Cc:** Harriët Blaauwgeers <[H.Blaauwgeers@iknl.nl](mailto:H.Blaauwgeers@iknl.nl)>  
**Subject:** Application OEI A&D Programme

Dear Michał,

Thank you for submitting the application for Maria Skłodowska-Curie National Research Institute of Oncology (MSCI) to the OEI A&D Programme.

## Member Profiles

k > Member Profiles

 **POLAND**

- **Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy**  
 Maria Skłodowska-Curie National Research Institute of Oncology  
<https://www.pib-nio.pl/>  
 ID: 129 **Full Member**

